Treatment reality of patients with BRAF-mutant advanced/metastatic melanoma in Switzerland in the era of choice

Cutaneous melanoma represents a major cause of cancer death in Europe. Without adequate therapy, the 5-year survival rate is 15–20% in distant metastatic disease. Evaluating the status quo of treatment standards in advanced melanoma and rationale for therapy decisions in Switzerland between January...

Descripción completa

Detalles Bibliográficos
Autores principales: Mangana, Joanna, Zihler, Deborah, Bossart, Simon, Brönnimann, Daniel, Zachariah, Ralph, Gérard, Camille Léa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2022
Materias:
Original Articles: Clinical Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9997623/
https://www.ncbi.nlm.nih.gov/pubmed/35855650
http://dx.doi.org/10.1097/CMR.0000000000000843

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9997623/
https://www.ncbi.nlm.nih.gov/pubmed/35855650
http://dx.doi.org/10.1097/CMR.0000000000000843

Ejemplares similares